

Seikagaku Announces the Establishment of a New Company in Canada

Seikagaku Corporation (Chiyoda-ku, Tokyo, Japan; “Seikagaku”) announced today the establishment of SEIKAGAKU NORTH AMERICA CORPORATION (the “New Company”) in Canada on January 25, 2022 as a wholly owned subsidiary of Dalton Chemical Laboratories, Inc., a subsidiary of Seikagaku.

The New Company will manage a portion of Seikagaku’s pharmaceutical and medical device development in North America. Seikagaku’s objectives for having a development base in North America are to formulate development plans more closely aligned with the local medical environment, to realize smooth communications with the U.S. Food and Drug Administration (FDA) and clinical trial sites, and to accelerate pharmaceutical and medical device development.

Seikagaku has articulated a vision of being “A company that is valued by the world through its innovative drug discovery” and is focusing on global expansion for products in development and existing products. By establishing the New Company at this time, Seikagaku will contribute to the health and well-being of people around the world by strengthening the R&D function in North America and linking this to the early and continuous development of pharmaceuticals and medical devices.

Overview of New Company

1. Company name:	SEIKAGAKU NORTH AMERICA CORPORATION
2. Location:	Toronto, Ontario Province, Canada
3. Date of establishment:	January 25, 2022
4. Start of operation:	March 2022 (planned)
5. Representative:	Hisatomo Kunii
6. Capital:	CAD10
7: Business description:	Development of pharmaceuticals and medical devices in North America

#####